Stock Performance and Price Movement
On 3 September 2026, Windlas Biotech Ltd's stock price surged to an intraday high of Rs.1117.95, representing a 2.24% increase on the day. This new peak surpasses the previous 52-week high, underscoring the stock’s robust upward trajectory over the past year. The stock has outperformed its sector by 0.26% on the day, reflecting relative strength within the Pharmaceuticals & Biotechnology industry.
The stock has recorded gains for three consecutive trading sessions, accumulating a total return of 10.28% during this period. This sustained upward movement has contributed to the stock’s overall 12.14% appreciation over the last 12 months, a performance that contrasts favourably with the broader Sensex index, which has declined by 4.61% over the same timeframe.
Technical Indicators and Moving Averages
Windlas Biotech is currently trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This alignment of moving averages signals a strong bullish trend and indicates positive momentum in the stock’s price action. The technical summary further supports this outlook, with the Moving Average Convergence Divergence (MACD) indicator showing bullish signals on both weekly and monthly charts.
Additional technical tools such as Bollinger Bands also reflect a bullish stance on weekly and monthly timeframes, while the Know Sure Thing (KST) indicator is mildly bearish on the monthly scale but bullish weekly. The Dow Theory readings suggest a mildly bullish trend across both weekly and monthly periods. The On-Balance Volume (OBV) indicator is mildly bullish on a weekly basis, indicating that volume trends are supporting the price advances.
Market Context and Sector Comparison
The broader market environment on 3 September 2026 saw the Sensex open 154.60 points higher and trade at 76,851.69, up 0.37% for the day. Despite this positive start, the Sensex has been on a three-week losing streak, declining by 1.48% during this span. The index is currently trading below its 50-day moving average, which itself is positioned below the 200-day moving average, signalling a cautious market backdrop.
Within this context, Windlas Biotech’s outperformance is notable, especially as mega-cap stocks are leading the market gains. The stock’s small-cap status and its ability to outperform both its sector and the broader market highlight its distinct momentum.
Mojo Score and Rating Update
According to MarketsMOJO, Windlas Biotech holds a Mojo Score of 62.0, which corresponds to a 'Hold' grade. This rating reflects an upgrade from a previous 'Sell' grade issued on 15 July 2026. The improvement in the Mojo Grade indicates a positive reassessment of the stock’s fundamentals and technical outlook by the rating agency. The stock’s market capitalisation is classified as small-cap, aligning with its current valuation and trading characteristics.
Price Range and Volatility
The stock’s 52-week low stands at Rs.699.35, illustrating a substantial price range of Rs.418.60 between the low and the new high. This range highlights the stock’s volatility and the strength of the recent rally that has propelled it to its current peak. The day’s price change of 0.38% further emphasises the stock’s steady upward momentum amid a mixed market environment.
Summary of Technical Signals
In summary, Windlas Biotech’s technical indicators predominantly signal bullish momentum. The convergence of positive MACD, Bollinger Bands, and moving averages across multiple timeframes supports the stock’s recent price advances. While some indicators such as the monthly KST show mild bearishness, the overall technical picture remains constructive.
This technical strength, combined with the stock’s outperformance relative to its sector and the broader market, underscores the significance of the new 52-week high milestone achieved on 3 September 2026.
